Fairmount Healthcare Fund II L.P. (CIK 1769651) reported 18 SEC Form 4 insider transactions across 8 companies over the past 18 months (most recent 2026-08-11). Recent activity: Buy APGE (31,838 shares), Buy APGE (10,370 shares), Buy CBIO (853,450 shares), Buy ORKA (3.6M shares), Sell ORKA (3.6M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Apogee Therapeutics, Inc. (APGE) | Director | Buy | 31,838 | $541,246 |
| 2026-08-11 | Apogee Therapeutics, Inc. (APGE) | Director | Buy | 10,370 | $454,724 |
| 2026-07-20 | CRESCENT BIOPHARMA, INC. (CBIO) | Director | Buy | 853,450 | $12.4M |
| 2026-07-01 | Oruka Therapeutics, Inc. (ORKA) | Director | Buy | 3.6M | $0 |
| 2026-07-01 | Oruka Therapeutics, Inc. (ORKA) | Director | Sell | 3.6M | $300.0M |
| 2026-06-23 | Spyre Therapeutics, Inc. (SYRE) | Director | Buy | 666,680 | $0 |
| 2026-06-23 | Spyre Therapeutics, Inc. (SYRE) | Director | Sell | 4.7M | $399.7M |
| 2026-05-13 | Viridian Therapeutics, Inc.\DE (VRDN) | Director | Buy | 1.2M | $20.0M |
| 2026-02-12 | Galecto, Inc. (GLTO) | Insider | Buy | 5.8M | $0 |
| 2026-02-12 | Galecto, Inc. (GLTO) | Insider | Buy | 2.9M | $0 |
| 2026-01-22 | Apogee Therapeutics, Inc. (APGE) | Director | Sell | 1.8M | $133.5M |
| 2025-12-08 | CRESCENT BIOPHARMA, INC. (CBIO) | Director | Buy | 1.4M | $18.2M |
| 2025-10-27 | Viridian Therapeutics, Inc.DE (VRDN) | Director | Buy | 454,545 | $10.0M |
| 2025-10-09 | Zenas BioPharma, Inc. (ZBIO) | Director | Buy | 316,219 | $6.0M |
| 2025-10-08 | Jade Biosciences, Inc. (JBIO) | Director | Buy | 1.3M | $12.2M |
| 2025-09-19 | Oruka Therapeutics, Inc. (ORKA) | Director | Buy | 333,340 | $5.0M |
| 2025-06-11 | Viridian Therapeutics, Inc.DE (VRDN) | Director | Buy | 1,600 | $12,480 |
| 2025-06-11 | Viridian Therapeutics, Inc.DE (VRDN) | Director | Buy | 12,500 | $153,875 |
Source: SEC Form 4 filings · as of 2026-08-11